• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page
FDA approves isatuximab in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

FDA approves isatuximab in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma

by MM360 Staff | Mar 31, 2021 | Featured News, Myeloma News

  The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior...
FDA Approves First CAR-T Cell Therapy ide-cel for R/R Myeloma

FDA Approves First CAR-T Cell Therapy ide-cel for R/R Myeloma

by MM360 Staff | Mar 27, 2021 | Featured News, Myeloma News

The U.S. Food and Drug Administration Approved Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel) (ide-cel), On Friday March 26th. Ide-cel is the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma. The treatment was...
Top Headlines and Journal Articles for the Week of March 22, 2021

Top Headlines and Journal Articles for the Week of March 22, 2021

by MM360 Staff | Mar 26, 2021 | Featured News, Myeloma News

Here is a roundup of articles and news stories the MYELOMA360 team found interesting this week.     Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions Researchers at Sylvester Comprehensive Cancer Center at the...
Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions

Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions

by MM360 Staff | Mar 25, 2021 | Featured News, Myeloma News

  Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that whole genome sequencing can help determine which patients with a multiple myeloma precursor condition, called MGUS or smoldering myeloma,...
COVID-19 in a Multiple Myeloma Patient

COVID-19 in a Multiple Myeloma Patient

by MM360 Staff | Mar 25, 2021 | Featured News, Myeloma News

Multiple myeloma patients are often treated with immunomodulatory drugs, proteasome inhibitors or monoclonal antibodies until disease progression. Chronic therapy in combination with the underlying disease frequently results in severe humoral and cellular...
« Older Entries
Next Entries »

Recent Content

  • Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
  • Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
  • ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
  • Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
  • Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
  • Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
  • Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT